A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI 2x160/4.5 µg Twice Daily and Budesonide AC pMDI 2x160 µg Twice Daily in Adult and Adolescent Asthmatics.

Trial Profile

A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI 2x160/4.5 µg Twice Daily and Budesonide AC pMDI 2x160 µg Twice Daily in Adult and Adolescent Asthmatics.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2015

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Mar 2014 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
    • 04 Mar 2014 Results presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top